Delivery Order SPE2DB20D1109-SPE2DB25FP05W
- Not listed
- The Defense Logistics Agency (DLA) awarded a $13,570.85 delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injections. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and a completion date of August 7, 2025. The pharmaceutical product will be performed and delivered from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a $1,172.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL pen injections with a ceiling value of $1,525.20. This competitive award, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a firm fixed-price delivery order with no set-aside designation. The contractor will perform at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injections valued at $11,887.80. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a pharmaceutical distributor and critical federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors on August 18, 2025, with a ceiling value of $3,291.68 and ultimate completion date of August 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors, with a contract ceiling value of $24,832.86 and an ultimate completion date of August 18, 2025. This is a firm fixed-price, competitive delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order valued at $11,057.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 ml pen injections on August 8, 2025. This firm fixed-price delivery order, with a completion date of August 11, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors in 0.5 mL quantities, with a ceiling value of $1,906.45. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and is scheduled for completion by August 28, 2025. The delivery order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP05WDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injections. This is a firm fixed-price delivery order valued at $4,007.01, with an ultimate completion date of May 13, 2025. The contract carries no set-aside designation and was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp's federal contract portfolio demonstrates its established capability as a major pharmaceutical distributor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through consistent, competitively awarded contracts across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 5/12/25 |